After 14 years at the top, Roche Chief Executive Officer Severin Schwan will step down from his role at the helm of the Swiss pharma giant next year. He will become the new chairman of the company’s board of directors upon the retirement of current chair Christoph Franz.
Beset by clinical holds and the termination of its former company head, CytoDyn Inc. has tapped Cyrus Arman as its new president and he is expected to take over the reins of the company as chief executive officer and be added to the board of directors within six months.
AbelsonTaylor has promoted Amy Restko to account planning director, acknowledging her leadership in developing successful insights-based marketing strategies for client brands.
Richard Marritt joined Xandar Kardian, a rapidly growing technology startup utilizing ultra-wide band radar signal processing for predictive health monitoring solutions.
To continue to support health and wellness companies’ rapidly expanding cultural relevance and dominance of global content, Havas Health & You (HH&Y) announced that industry veteran Dan Rubin will join the network. He will work closely with global executive leadership and existing President and CCO Allison Ceraso to shape the future vision for Havas Health +, a fully integrated experience agency on the rise. Havas Health + has generated double-digit growth for the past 3 years, growing both HCP and DTC practices through new client wins and brand launches.
Outcomes LLC, publisher of market-leading Med Ad News magazine and PharmaLive.com for the life sciences industry, strengthens its leadership team with the addition of Director of Content, Maria Fontanazza. Maria adds more than 20 years of experience in journalism, marketing, and communications. She was previously Editor-in-Chief at Innovative Publishing Company Inc., covering medical devices and additional FDA-regulated markets.
Inovio Pharmaceuticals announced a leadership change at the helm and the discontinuation of a Phase III COVID-19 vaccine study.
Moderna Inc. Chief Financial Officer Jorge Gomez departed a day after taking charge, the vaccine maker said on May 11, following his former employer disclosing an internal probe related to financial reporting.
Johnson & Johnson on May 11 appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of 2023.
Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.
Reuters